Literature DB >> 2572438

Demonstration of alpha 1A- and alpha 1B-adrenoceptor binding sites in human brain tissue.

G Gross1, G Hanft, H M Mehdorn.   

Abstract

Radioligand binding studies suggest that alpha 1-adrenoceptor recognition sites are heterogeneous. Several adrenergic agents discriminate between two adrenoceptor binding sites designated alpha 1A and alpha 1B. In the present study we demonstrate for the first time that these two subtypes exist in the human brain. 5-Methyl-urapidil and (+)-niguldipine, which have previously been shown to be alpha 1A-selective, inhibited [3H]prazosin binding to cortical membranes in a biphasic manner. The irreversible alpha 1B-ligand, chloroethylclonidine, preferentially eliminated the binding sites with low affinity for (+)-niguldipine. In contrast, BE 2254 and unlabelled prazosin displaced the radioligand in a monophasic manner. The IC50 values for prazosin were not affected by pretreatment of the membranes with chloroethylclonidine. Our data on human brain membranes are in excellent agreement with recent findings in rat tissues and suggest that the alpha 1-adrenoceptor subtypes in human brain are similar to those in rat tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572438     DOI: 10.1016/0014-2999(89)90032-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Alpha 1 B- but not alpha 1 A-adrenoceptors mediate inositol phosphate generation.

Authors:  M C Michel; G Hanft; G Gross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

2.  Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.

Authors:  George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

3.  Alpha 1A and alpha 1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex.

Authors:  M C Michel; R Büscher; T Philipp; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  Commentary: Doxazosin for alcoholism.

Authors:  Lorenzo Leggio; George A Kenna
Journal:  Alcohol Clin Exp Res       Date:  2012-12-27       Impact factor: 3.455

Review 5.  Noradrenergic targets for the treatment of alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Robert M Swift; Lorenzo Leggio
Journal:  Psychopharmacology (Berl)       Date:  2018-02-20       Impact factor: 4.530

6.  The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder.

Authors:  Florence P Varodayan; Reesha R Patel; Alessandra Matzeu; Sarah A Wolfe; Dallece E Curley; Sophia Khom; Pauravi J Gandhi; Larry Rodriguez; Michal Bajo; Shannon D'Ambrosio; Hui Sun; Tony M Kerr; Rueben A Gonzales; Lorenzo Leggio; Luis A Natividad; Carolina L Haass-Koffler; Rémi Martin-Fardon; Marisa Roberto
Journal:  Biol Psychiatry       Date:  2022-04-13       Impact factor: 12.810

Review 7.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

8.  Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.

Authors:  B A Kenny; A M Naylor; P M Greengrass; M J Russell; S J Friend; A M Read; M G Wyllie
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Authors:  D R Blue; D W Bonhaus; A P Ford; J R Pfister; N A Sharif; I A Shieh; R L Vimont; T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Synthesis and Characterization of Carbon-11 Labeled Iloperidone for Imaging of α1-Adrenoceptor in Brain.

Authors:  Yulong Xu; Yanli Wang; Hao Wang; Changning Wang
Journal:  Front Mol Biosci       Date:  2020-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.